346 related articles for article (PubMed ID: 23879434)
61. Effects of recombinant human growth hormone on intestinal translocation of bacteria and endotoxin in rats with obstructive jaundice.
Yang ZW; Li JG; Mao XG; Sun B; Tong ZS; Sun HY; Li XR; Cong YP
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):445-9. PubMed ID: 16109534
[TBL] [Abstract][Full Text] [Related]
62. Bacterial translocation in a rat model of large volume hepatic radiofrequency ablation.
Ypsilantis P; Panopoulou M; Lambropoulou M; Tsigalou C; Pitiakoudis M; Tentes I; Kartali S; Papachristou F; Papadopoulos N; Simopoulos C
J Surg Res; 2010 Jun; 161(2):250-8. PubMed ID: 19524266
[TBL] [Abstract][Full Text] [Related]
63. Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis.
Conlin VS; Wu X; Nguyen C; Dai C; Vallance BA; Buchan AM; Boyer L; Jacobson K
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G735-50. PubMed ID: 19661153
[TBL] [Abstract][Full Text] [Related]
64. Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease.
Stärkel P; Schnabl B
Semin Liver Dis; 2016 Sep; 36(4):331-339. PubMed ID: 27997973
[TBL] [Abstract][Full Text] [Related]
65. Role of the gut in multiple organ failure: bacterial translocation and permeability changes.
Swank GM; Deitch EA
World J Surg; 1996 May; 20(4):411-7. PubMed ID: 8662128
[TBL] [Abstract][Full Text] [Related]
66. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.
Ilan Y
World J Gastroenterol; 2012 Jun; 18(21):2609-18. PubMed ID: 22690069
[TBL] [Abstract][Full Text] [Related]
67. Changes of Intestinal Functions in Liver Cirrhosis.
Fukui H; Wiest R
Inflamm Intest Dis; 2016 Apr; 1(1):24-40. PubMed ID: 29922655
[TBL] [Abstract][Full Text] [Related]
68. Microbiome and bacterial translocation in cirrhosis.
Gómez-Hurtado I; Such J; Francés R
Gastroenterol Hepatol; 2016 Dec; 39(10):687-696. PubMed ID: 26775042
[TBL] [Abstract][Full Text] [Related]
69. Intestinal permeability in a patient with liver cirrhosis.
Aguirre Valadez JM; Rivera-Espinosa L; Méndez-Guerrero O; Chávez-Pacheco JL; García Juárez I; Torre A
Ther Clin Risk Manag; 2016; 12():1729-1748. PubMed ID: 27920543
[TBL] [Abstract][Full Text] [Related]
70. Targeting the gut-liver-immune axis to treat cirrhosis.
Tranah TH; Edwards LA; Schnabl B; Shawcross DL
Gut; 2021 May; 70(5):982-994. PubMed ID: 33060124
[TBL] [Abstract][Full Text] [Related]
71. [Intestinal permeability in patients with viral and alcoholic liver disease].
Kim JW; Jeon WK; Yun JW; Park DI; Cho YK; Sung IK; Park CY; Sohn CI; Kim BI; Kim EJ; Shin MS
Korean J Gastroenterol; 2004 Feb; 43(2):104-11. PubMed ID: 14978367
[TBL] [Abstract][Full Text] [Related]
72. Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis.
Assimakopoulos SF; Tsamandas AC; Tsiaoussis GI; Karatza E; Zisimopoulos D; Maroulis I; Kontogeorgou E; Georgiou CD; Scopa CD; Thomopoulos KC
Ann Hepatol; 2013; 12(2):301-7. PubMed ID: 23396742
[TBL] [Abstract][Full Text] [Related]
73. Markers of immunity and bacterial translocation in cirrhosis.
Mortensen C
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183053
[TBL] [Abstract][Full Text] [Related]
74. Low potassium disrupt intestinal barrier and result in bacterial translocation.
Wu H; Huang R; Fan J; Luo N; Yang X
J Transl Med; 2022 Jul; 20(1):309. PubMed ID: 35794599
[TBL] [Abstract][Full Text] [Related]
75. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.
Tsiaoussis GI; Assimakopoulos SF; Tsamandas AC; Triantos CK; Thomopoulos KC
World J Hepatol; 2015 Aug; 7(17):2058-68. PubMed ID: 26301048
[TBL] [Abstract][Full Text] [Related]
76. The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction-associated steatotic liver disease.
Bergheim I; Moreno-Navarrete JM
Eur J Clin Invest; 2024 Jul; 54(7):e14224. PubMed ID: 38634717
[TBL] [Abstract][Full Text] [Related]
77. Role of intestinal permeability in monitoring mucosal barrier function. History, methodology, and significance of pathophysiology.
Sun Z; Wang X; Andersson R
Dig Surg; 1998; 15(5):386-97. PubMed ID: 9845620
[TBL] [Abstract][Full Text] [Related]
78. Effect of uremic state in intestine through a co-culture in vitro intestinal epithelial model.
Garcia A; Macedo MH; Azevedo MJ; Pestana M; Sarmento B; Sampaio-Maia B
Int J Pharm; 2020 Jun; 584():119450. PubMed ID: 32464229
[TBL] [Abstract][Full Text] [Related]
79. The shaping of gut immunity in cirrhosis.
Muñoz L; Caparrós E; Albillos A; Francés R
Front Immunol; 2023; 14():1139554. PubMed ID: 37122743
[TBL] [Abstract][Full Text] [Related]
80. [Intestinal permeability and cirrhosis].
Ancel D; Barraud H; Peyrin-Biroulet L; Bronowicki JP
Gastroenterol Clin Biol; 2006 Mar; 30(3):460-8. PubMed ID: 16633314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
